Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/22/2021 11/23/2021 11/24/2021 11/26/2021 11/29/2021 Date
7.05(c) 6.81(c) 7.07(c) 6.97(c) 6.92(c) Last
11 102 914 4 041 970 2 607 711 1 161 682 1 563 206 Volume
+4.75% -3.40% +3.82% -1.41% -0.72% Change
More quotes
Estimated financial data (e)
Sales 2021 38,1 M 43,1 M 43,1 M
Net income 2021 -56,0 M -63,3 M -63,3 M
Net cash position 2021 172 M 194 M 194 M
P/E ratio 2021 -13,0x
Yield 2021 -
Sales 2022 52,9 M 59,8 M 59,8 M
Net income 2022 -59,6 M -67,4 M -67,4 M
Net cash position 2022 93,0 M 105 M 105 M
P/E ratio 2022 -11,8x
Yield 2022 -
Capitalization 754 M 852 M 853 M
EV / Sales 2021 15,3x
EV / Sales 2022 12,5x
Nbr of Employees 153
Free-Float 97,2%
More Financials
Company
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28... 
Sector
Biotechnology & Medical Research
Calendar
12/13 | 06:00pmPresentation
More about the company
Ratings of Affimed N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AFFIMED N.V.
11/22Health Care Stocks Finishing Mixed This Afternoon
MT
11/22Health Care Stocks Drifting Near Unchanged Mark Monday
MT
11/22Affimed NV's Innate Cell Engager Achieves 100% Objective Response Rate In Phase 1/2 Lym..
MT
11/22Wall Street Sees Upbeat Open as Potential China Easing Lifts Sentiment
MT
11/22Top Premarket Gainers
MT
11/22AFFIMED N : Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of C..
PU
11/22Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Co..
GL
11/22Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 St..
CI
11/17Berenberg Bank Initiates Coverage on Affimed With Buy Rating, $11 Price Target
MT
11/16AFFIMED N : Jefferies London Healthcare Conference 2021 - Virtual
PU
11/15Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at t..
AQ
11/13AFFIMED N : Stifel 2021 Virtual Healthcare Conference
PU
11/12Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at t..
GL
11/12Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at t..
GL
11/12Affimed N.V. Announces Preclinical Data of its Innate Cell Engagers at the 36th Annual ..
CI
More news
News in other languages on AFFIMED N.V.
11/22Les actions du secteur de la santé terminent en demi-teinte cet après-midi
11/22Les actions du secteur de la santé dérivent près de la marque inchangée lundi
11/22Innate Cell Engager d'Affimed NV obtient un taux de réponse objective de 100% dans une ..
11/10AFFIMED : perte accrue au troisième trimestre et baisse du chiffre d'affaires ; dépôt d'un..
11/10Earnings Flash (AFMD) AFFIMED N.V. annonce un chiffre d'affaires de 8,7 millions d'euro..
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | AFMD | NL0010872420 | MarketScreener
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 6,13 €
Average target price 11,38 €
Spread / Average Target 85,7%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Executive Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.19.76%858
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.27.38%64 416
VERTEX PHARMACEUTICALS-22.32%46 678